Core Viewpoint - Altimmune, Inc. (NASDAQ: ALT) faces a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [1]. Group 1: Company Performance - On June 26, 2025, Altimmune reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [1]. Group 2: Legal Proceedings - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for October 6, 2025 [2]. - The Gross Law Firm is leading the class action, aiming to protect investors who suffered losses due to misleading statements from the company [3].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [8]. Next Steps - Investors who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors can join the action without any out-of-pocket fees through a contingency fee arrangement [1][2]. - Investors wishing to serve as lead plaintiff must file with the Court by October 6, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, claiming they had reliable information while failing to meet a key statistical significance marker for fibrosis reduction [4]. - The company is accused of inflating expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the trial's topline results [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, with a reminder of the upcoming deadline for investors to seek lead plaintiff status in a federal securities class action [2][3][4]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction, despite prior inflated expectations [3]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [4]. Group 2: Legal Actions - Investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is reminding investors of the October 6, 2025, deadline to seek the role of lead plaintiff in the class action lawsuit against Altimmune [2][5].

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virt ...

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

PHILADELPHIA , Sept. 22, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Class Period"). ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6]. Group 1: Company Overview - Altimmune, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol ALT [4]. - The company recently reported topline results from the IMPACT Phase 2b MASH trial, which did not meet statistical significance for its primary endpoint [6]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, to discuss their legal options [1][4]. - There is a deadline of October 6, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4]. Group 3: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in just one day [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form online or contact the law firm directly for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker related to fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]